ERBB Fusion clinical trials at UC Cancer

• Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

  open to eligible people ages 18 years and up

  Open-label, Phase 2, single treatment arm, 3 cohorts

  at UC Irvine UCSF

Last updated: August 10, 2020